Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review

November 2021 | 49 pages | ID: BEA6D85F24FEN
GlobalData

Abstracts

Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and markets dermatological medications and medical cosmetics. The company’s products comprises of Ameluz, BF-RhodoLED, Xepi, Aktipak and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera’s BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. Belixos is a cosmetic product, indicated for regenerative care of reddened and inflamed skin. Its Belixos line of products include Belixos creme, Belixos liquid, Belixos gel, and Belixos protect. The company distributes its products through pharmaceutical wholesalers and licensing partners. Biofrontera is headquartered in Leverkusen, Germany.

Biofrontera AG Key Recent Developments

Nov 18,2021: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
Oct 01,2021: Biofrontera reports preliminary approximate revenues for the month of September 2021
Sep 08,2021: Biofrontera reports preliminary revenue for the month of August 2021
Aug 19,2021: Biofrontera reports financial results for the six months ended June 30, 2021
Aug 09,2021: Biofrontera reports preliminary revenue for the month of July 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Biofrontera AG - Key Facts
Biofrontera AG - Key Employees
Biofrontera AG - Key Employee Biographies
Biofrontera AG - Major Products and Services
Biofrontera AG - History
Biofrontera AG - Company Statement
Biofrontera AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Biofrontera AG - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Other regions
Performance
Geographical Segment: The US
Performance
R&D Overview
Biofrontera AG - SWOT Analysis
SWOT Analysis - Overview
Biofrontera AG - Strengths
Biofrontera AG - Weaknesses
Biofrontera AG - Opportunities
Biofrontera AG - Threats
Biofrontera AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biofrontera AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 18, 2021: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
Oct 01, 2021: Biofrontera reports preliminary approximate revenues for the month of September 2021
Sep 08, 2021: Biofrontera reports preliminary revenue for the month of August 2021
Aug 19, 2021: Biofrontera reports financial results for the six months ended June 30, 2021
Aug 09, 2021: Biofrontera reports preliminary revenue for the month of July 2021
Jul 06, 2021: Biofrontera reports preliminary revenue for the month of June 2021
Jun 07, 2021: Biofrontera reports preliminary revenue for the month of May 2021
May 11, 2021: Biofrontera reports Q1 2021 financial results
Apr 12, 2021: Biofrontera reports results for the 2020 financial year
Mar 31, 2021: Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Biofrontera AG, Key Facts
Biofrontera AG, Key Employees
Biofrontera AG, Key Employee Biographies
Biofrontera AG, Major Products and Services
Biofrontera AG, History
Biofrontera AG, Subsidiaries
Biofrontera AG, Key Competitors
Biofrontera AG, Ratios based on current share price
Biofrontera AG, Annual Ratios
Biofrontera AG, Annual Ratios (Cont...1)
Biofrontera AG, Annual Ratios (Cont...2)
Biofrontera AG, Interim Ratios
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biofrontera AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Biofrontera AG, Performance Chart (2016 - 2020)
Biofrontera AG, Ratio Charts
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021